Showing results (121-130 of 241) with videos related to

Sort By:
Pageof 25
Journal of Global Oncology|July 19, 2017
End-of-Life Care in Latin AmericaEnrique Soto-Perez-de-Celis, Yanin Chavarri-Guerra, Tania Pastrana, et al.
Steroids|June 26, 2007
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapyRichard J Santen, Lawrence Demers, Susan Ohorodnik, et al.
Cancer Research|September 1, 1986
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II reportP E Goss, T J Powles, M Dowsett, et al.
Breast Cancer Research and Treatment|December 16, 2014
Pregnancy-associated breast cancer in women from Shanghai: risk and prognosisKathrin Strasser-Weippl, Ritesh Ramchandani, Lei Fan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2016
Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17Rachel A Goodwin, Rahima Jamal, Christopher M Booth, et al.
Breast (Edinburgh, Scotland)|April 9, 2016
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17P E R Liedke, D Tu, L Shepherd, et al.
Breast Cancer Research and Treatment|August 16, 2011
Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterusPaul E Goss, Shangle Qi, Haiqing Hu, et al.
Seminars in Oncology|April 1, 1990
A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary reportF A Shepherd, P E Goss, J Latreille, et al.
Pharmacogenomics|August 13, 2015
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphismsLaura R Parham, Linda P Briley, Karen S King, et al.
Cancer Research|April 1, 1987
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and routeM Dowsett, P E Goss, T J Powles, et al.
Pageof 25